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ABSTRACT
Background: In the clinical management of patients at risk for or diagnosed
with primary open-angle glaucoma (POAG), the aim of medical treatment is to
reduce intraocular pressure (IOP) and then maintain it over time at a level that
preserves both the structure and function of the optic nerve.
Objective: The objective of this report was to establish a consensus on the
criteria that should be used to determine the characteristics of IOP-lowering
medication.
Methods: Discussion was held among a panel of 12 physicians considered
to be experts in glaucoma to develop a consensus on the criteria used by them
to determine the characteristics of the IOP-lowering medication chosen for ini-
tial monotherapy and adjunctive treatment of ocular hypertension (OHT) or
POAG. Consensus development combined available evidence and the impres-
sions of these physicians regarding the clinical effectiveness of IOP-lowering
medication for OHT and POAG. Once the panel identified the criteria, the order
of priority and the relative importance of these criteria were then established
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in the setting of 3 risk categories (low, medium, and high) for a patient to expe-
rience significant visual disability from glaucoma over their expected life span.
Results: The panel identified 5 criteria to determine the characteristics of
IOP-lowering medication for OHT and POAG: IOP-lowering effect, systemic ad-
verse events (AEs), ocular tolerability, compliance/administration, and cost of
treatment. IOP-lowering effect was consistently ranked as the highest priority
and cost as the lowest. The priority of compliance/administration did not vary
by clinical situation. Systemic AEs and ocular tolerability were ranked as higher
priorities in initial monotherapy than in adjunctive treatment and ranked lower
as the risk for visual disability increased. The priority given to the criteria used
to determine clinical effectiveness varied both with the risk for functional
vision loss from glaucoma and whether initial monotherapy or adjunctive treat-
ment was being considered. 
Conclusion: Glaucoma treatment should be assessed with regard to the
need not only to lower IOP but also to minimize systemic and ocular AEs, pro-
mote patient compliance, and minimize cost. The order of priority and relative
importance given to these treatment criteria will vary as part of individualizing
patient care. (Curr Ther Res Clin Exp. 2007;68:127–136) Copyright © 2007 Excerpta
Medica, Inc.
Key words: consensus, criteria, intraocular pressure, glaucoma.
INTRODUCTION
In the clinical management of patients at risk for or diagnosed with primary
open-angle glaucoma (POAG), the aim of medical treatment is to reduce intraoc-
ular pressure (IOP) and then maintain it over time at a level that preserves both
the structure and function of the optic nerve. In recent years, the indirect evi-
dence that had long provided the rationale for IOP lowering as the therapeutic
goal of glaucoma management1–4 has been bolstered by direct evidence that
reducing IOP prevents or delays the onset of POAG5 and the progression of the
disease.6–9
The IOP-lowering effect of an ocular hypotensive medication might be
assumed to be synonymous with its effectiveness in managing patients with
ocular hypertension (OHT) or POAG. However, one distinction between efficacy
and effectiveness is that the former refers to the outcome as it pertains to a par-
ticularly important variable, such as IOP in glaucoma patients, while the latter
relates to the overall outcome of an intervention, taking all important variables
into consideration.10 Several factors besides IOP-lowering effect contribute to
the effectiveness of medical treatment for OHT and POAG. Systemic adverse
events (AEs), ocular tolerability, frequency of administration (which might im-
pact compliance), and the cost of treatment are some of the important vari-
ables that ophthalmologists have to consider when selecting treatment.
Another critical aspect of clinical decision making in managing glaucoma is
to ensure that any intervention reflects an appropriate balance between the
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patient’s risk for adverse outcomes due to disease progression and the poten-
tial benefit and risk for harm from treatment.
Glaucomatous optic nerve damage can be considered a disease continuum,11
beginning with the earliest undetectable changes associated with apoptosis,
progressing through stages of damage to the optic nerve, and ultimately lead-
ing in some cases to blindness.12 Patients are first seen by an ophthalmologist
at different stages of the continuum and their conditions progress at varying
rates. The likelihood of ultimate functional vision loss from glaucoma in a given
patient is determined by the disease stage at the time of diagnosis, the rate of
progression, and the patient’s life span.13 All of these variables make it difficult
to judge whether a patient is likely to experience glaucomatous vision loss, as
well as how this likelihood should be reflected in any intervention. When con-
sidering medical IOP-lowering treatment, part of individualizing the clinical
management of each patient perceived to be at risk for vision loss might require
changing the relative priority given to the factors that contribute to clinical
effectiveness, depending on the magnitude of that risk.
New therapeutic agents for glaucoma have become available during the pre-
vious decade. For most of the twentieth century, medical management of glau-
coma relied on cholinergic agents, such as pilocarpine and carbachol. In the
late 1970s there was a shift to β-adrenergic blockers. In the late 1990s several
new classes of topical medications to treat glaucoma—prostaglandin analogues
(latanoprost, travoprost, bimatoprost), selective α-adrenergic agonists (apra-
clonidine, brimonidine, clonidine), and carbonic anhydrase inhibitors (brin-
zolamide, dorzolamide)—were introduced. Each of these medications has a
unique profile in terms of the criteria for clinical effectiveness,13 presenting the
ophthalmologist with greater opportunities, but also with greater challenges,
with respect to appropriately individualizing treatment.
To assist the general ophthalmologist in clinical decision-making, profes-
sional groups around the world have published guidelines on the diagnosis and
treatment of glaucoma.13–15 These standards continue to evolve, as exemplified
by the change in the European Glaucoma Society guidelines between the first
edition in 1998, in which a specific recommendation was made regarding initial
monotherapy, and the second edition in 2003, which leaves the choice of initial
monotherapy to the judgment of the individual physician.
Early intervention to prevent or delay the onset and progression of glau-
coma5,6 and advances in diagnostic technology, such as quantitative imaging
and selective functional tests that offer the prospect of detecting glaucoma earlier
than ever before, are important reasons to treat glaucoma as soon as possible and
in the most effective manner. When glaucoma is diagnosed at a late stage, the
emphasis is generally on maximal lowering of IOP.13 In our opinion, the impor-
tance of other variables that determine clinical effectiveness at various stages
of the disease have not been well studied and there is a lack of objective evi-
dence on which to base recommendations about medication-selection criteria
and individualizing treatment according to risk for glaucomatous vision loss.
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Within the framework of evidence-based medicine, however, using a panel
approach to incorporate expert opinion by those familiar with available scien-
tific evidence and experienced in clinical practice is accepted as a valid way of
providing an overview of clinical decision-making in circumstances where the
evidence alone is not enough to make such recommendations.
This paper is based on the conclusions of a panel of glaucoma specialists.
The objective of the panel was to establish a consensus on the criteria that
should be used to determine the characteristics of the IOP-lowering medication
chosen for initial monotherapy and adjunctive treatment of OHT or POAG, tak-
ing into consideration the level of risk for significant visual disability in un-
treated patients at different stages of the disease continuum.
PATIENTS AND METHODS
A panel of 12 glaucoma specialists convened at a roundtable discussion in
Amsterdam, The Netherlands, for 2 days in September 2004. Panelists were con-
sidered experts in glaucoma with clinical experience and ongoing research
interests in glaucoma and were selected to provide expert opinion in glaucoma
management. Panelists were drawn from a broad cross-section of worldwide
practice in the European Union, United States, Canada, and Australia. The panel
included representatives from the executive committees of both the American
and the European Glaucoma Societies, and between them have published over
300 peer-reviewed articles.
Individual experience and opinions were pooled to identify the criteria the
panelists considered to select initial monotherapy or adjunctive treatment to
control IOP, once they decided that such treatment was warranted. To be
included in the discussion, a criterion had to be considered an integral factor
in the clinical effectiveness of medical treatment and had to allow the ophthal-
mologist to discern meaningful differences between medications when choos-
ing a treatment. Having identified such criteria, the panel then considered the
order of priority and the relative importance of the criteria within the context
of 6 hypothetical clinical situations. These situations specified levels of risk for
significant visual disability over a patient’s lifetime as being low, medium, or
high, and were further stratified based on whether treatment was initial or
adjunctive. The panel considered a number of real-life case histories to reach a
common understanding of these risk categories; however, no attempt was made
to define the categories.
Data were to be collected for each criterion in turn for each clinical situation.
All panelists were required to express their views in every case. Group discus-
sion was to continue until a consensus view was reached for every question.
Consensus was defined as acceptance by all of the panelists.
A numeric ranking system was used to assign priorities; the same value
might be assigned to multiple criteria. Views on relative importance were deter-
mined by asking panelists to assign a percentage value to each criterion. The
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sum of the percentages applied to all criteria for a given clinical situation had
to total 100%.
RESULTS
The panel agreed on 5 criteria to consider when making decisions regarding
medical treatment for OHT and POAG. The first 4—IOP-lowering effect, sys-
temic AEs, ocular tolerability, and compliance/administration—were criteria
that the panel considered to be prerequisites for effective treatment and to pro-
vide a basis for meaningful differentiation between alternative medications. The
fifth criterion, the need to minimize cost, was included to acknowledge the cen-
tral importance of economic considerations in the real world. The panel consid-
ered the potential for a positive effect on ocular blood flow as a possible crite-
rion, but rejected it because there is insufficient evidence to determine what
constitutes a positive effect. It was agreed that advances in measuring blood
flow would be needed before making any determinations about the relative
effect of glaucoma medications on blood flow. Similarly, it was agreed that there
was insufficient evidence to support any non–IOP-lowering (ie, neuroprotec-
tive) benefit of existing treatment.
The results of the ranking exercises are shown in Figures 1 and 2. The need
to reduce IOP was allocated the highest priority in every clinical situation, and
systemic AEs and ocular tolerability were considered as important as reducing
IOP in the case of initial monotherapy in patients at low risk for significant
visual impairment (Figure 1). The need to maximize the likelihood of patient
adherence was ranked highly and fairly uniformly across most clinical situa-
tions. In each clinical situation, the lowest priority was given to the need to mini-
mize cost.
The importance of IOP-lowering effect was ranked progressively higher as
risk increased and higher for adjunctive treatment than initial monotherapy
within each risk category (Figure 2). The systemic AEs criterion was ranked
lower as the level of risk for visual impairment increased, as was ocular tolera-
bility, although the latter criterion was considered more important in initial
monotherapy treatment for a patient at medium risk than in adjunctive treat-
ment for a patient at low risk. In a patient at low risk for significant visual
impairment, compliance/administration was assigned a lower relative impor-
tance in initial monotherapy than adjunctive treatment. The reverse was true in
the other 2 risk categories. Cost was assigned a relative importance value only
in the low-risk category.
DISCUSSION
The panel formed a consensus view on 2 fundamental issues. First, the poten-
tial clinical effectiveness of medical IOP-lowering treatment needs to be consid-
ered with reference to a number of criteria. Second, in selecting medical treat-
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Figure 1. Panelists’ priority (1 = high; 5 = low) rating for each of the treatment crite-
ria in initial monotherapy and adjunctive medical treatment of glaucoma by
risk for significant visual disability (low, medium, and high). IOP = intraocu-
lar pressure; AEs = adverse events.
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ment, these criteria need to be weighed uniquely for each patient, based on the
risk to the patient of significant visual disability from glaucoma over their lifetime.
The panel determined that the choice of clinically effective medical IOP-
lowering treatment depends on a composite of needs: to lower IOP; to minimize
the risk for systemic AEs; to minimize ocular AEs; to maximize the likelihood of
a patient adhering to the regimen; and to minimize cost.
Selecting a treatment that effectively lowers IOP in all clinical scenarios was
given primary importance because this is currently the only intervention
found to prevent or delay the onset and progression of glaucoma.2,5–7,9 Only in
the case of initial monotherapy for a patient considered at low risk for visual
impairment was the need to minimize both the risk for systemic and ocular AEs
given the same priority as the need to lower IOP. In a similar patient where
adjunctive treatment was indicated, the panel agreed that the degree of IOP
lowering superseded the importance of systemic AEs and ocular tolerability.
The relative importance assigned to IOP lowering among the treatment goals
increased as disease state became progressively more severe.
The need to facilitate patient compliance16–18 was the other criterion that was
ranked consistently across all clinical situations. The panelists’ views followed a
similar pattern for IOP lowering and compliance/administration. Both of these
criteria were considered important, and compared with systemic AEs and ocular
tolerability, they became relatively more important as the risk for visual impair-
ment increased, because the threat to the patient’s quality of life from the path-
ology may come to outweigh the threat posed by potential AEs from treatment.
Also, the need to lower IOP can be met only if the patient adheres to the medica-
tion regimen, thus linking IOP lowering and compliance/administration.
The 2 criteria associated with the greatest variation across clinical situations
were systemic AEs and ocular tolerability. This suggests that the panel consid-
ered these 2 criteria to be the principal mechanisms for individualizing medical
treatment. Considering how to balance the risk for harm from glaucoma with
the risk for harm from treatment is the focus of the clinical decision-making
process. As far as we are aware, no attempt had previously been made to quan-
tify the relative importance of medication tolerability versus IOP-lowering effect
along the continuum of risk for glaucomatous vision loss.
Limitations
One potential limitation of this consensus was the panel’s approach to the
need to minimize cost. Pharmacoeconomic considerations are often more com-
plex than—and cannot be studied as easily as—some of the other criteria. Cost
considerations vary widely from country to country and across different health-
care systems. The panel decided to include the need to minimize cost as a cri-
terion and consistently assigned cost the lowest priority. These findings indi-
cate that perhaps this criterion needs to be addressed separately.
A second limitation concerns the categorization of risk for significant visual
disability. What constitutes significant visual disability can vary greatly. Because
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the panel did not develop an objective definition, the risk categories (low,
medium, and high) were also left undefined. However, given the currently lim-
ited ability of ophthalmologists to directly monitor and assess glaucomatous
change, to precisely calculate rate of progression, or to determine how these
will influence whether a patient is likely to experience visual impairment due to
glaucoma in their lifetime, it seems reasonable to regard the question of risk for
significant visual disability as a matter for the subjective judgment of the indi-
vidual physician. 
CONCLUSION
Glaucoma treatment should be assessed with regard to the need not only to
lower IOP but also to minimize systemic and ocular AEs, promote patient com-
pliance, and minimize cost. The order of priority and relative importance given
to these treatment criteria will vary as part of individualizing patient care.
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